{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:54:49Z","timestamp":1718020489963},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00277-010-1009-y","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T13:30:59Z","timestamp":1276608659000},"page":"365-366","source":"Crossref","is-referenced-by-count":6,"title":["The myeloproliferative neoplasm-associated JAK2 46\/1 haplotype is not overrepresented in chronic myelogenous leukemia"],"prefix":"10.1007","volume":"90","author":[{"given":"Ambra","family":"Spolverini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy V.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"1009_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","volume":"59","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Tefferi A (2009) Advances in understanding and management of myeloproliferative neoplasms. AC-A Cancer J Clin 59:171\u2013191","journal-title":"AC-A Cancer J Clin"},{"key":"1009_CR2","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","volume":"112","author":"O Landgren","year":"2008","unstructured":"Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M (2008) Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24577 first-degree relatives of 11039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199\u20132204","journal-title":"Blood"},{"key":"1009_CR3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446\u2013449","journal-title":"Nat Genet"},{"key":"1009_CR4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","volume":"41","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450\u2013454","journal-title":"Nat Genet"},{"key":"1009_CR5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","volume":"41","author":"O Kilpivaara","year":"2009","unstructured":"Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455\u2013459","journal-title":"Nat Genet"},{"key":"1009_CR6","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2009.110","volume":"23","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, Passamonti F, Lippert E, Carillo S, Girodon F, Vannucchi A, Reading NS, Prchal JT, Ay C, Pabinger I, Gisslinger H, Kralovics R (2009) The \u2018GGCC\u2019 haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23:1924\u20131926","journal-title":"Leukemia"},{"key":"1009_CR7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","volume":"24","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, Tefferi A (2010) The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 24:110\u2013114","journal-title":"Leukemia"},{"key":"1009_CR8","doi-asserted-by":"crossref","unstructured":"Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K, Percy M, McMullin F, Scott LM, Tapper W, Silver RT, Oscier D, Harrison CH, Grallert H, Chase AJ, Gree AR, Cross NCP (2010) The JAK2 46\/1 haplotype predisposes to myeloproliferative neoplasms characterized by diverse mutations. Blood (in press)","DOI":"10.1182\/blood-2009-08-236448"},{"key":"1009_CR9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/leu.2010.1","volume":"24","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, Lasho T, Finke C, Gangat N, Caramazza D, Siragusa S, Hanson C, Pardanani A, Tefferi A (2010) MPL mutation effect on JAK2 46\/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia 24:859\u2013860","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1009-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-1009-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1009-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T03:34:03Z","timestamp":1559187243000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-1009-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-1009-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}